Solventum (NYSE:SOLV) Price Target Raised to $105.00 at Piper Sandler

Solventum (NYSE:SOLV) had its price objective lifted by analysts at Piper Sandler from $92.00 to $105.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Piper Sandler’s price objective would suggest a potential upside of 25.74% from the stock’s current price.

SOLV has been the subject of several other research reports. KeyCorp raised their price objective on shares of Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a research report on Thursday. BTIG Research increased their target price on shares of Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday. UBS Group restated a “buy” rating and issued a $101.00 price target on shares of Solventum in a report on Thursday. BMO Capital Markets began coverage on shares of Solventum in a report on Wednesday, July 8th. They set a “market perform” rating and a $81.00 price objective on the stock. Finally, Wells Fargo & Company reduced their target price on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 6th. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $91.64.

Solventum Trading Down 4.5%

Shares of NYSE:SOLV traded down $3.96 during midday trading on Thursday, reaching $83.50. The company’s stock had a trading volume of 813,693 shares, compared to its average volume of 1,409,545. Solventum has a fifty-two week low of $62.38 and a fifty-two week high of $90.00. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The firm has a 50 day moving average price of $79.09 and a two-hundred day moving average price of $74.36. The firm has a market capitalization of $14.46 billion, a price-to-earnings ratio of 10.24, a PEG ratio of 1.36 and a beta of 0.60.

Solventum (NYSE:SOLV) last released its earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The business had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.15 billion. During the same quarter last year, the firm posted $1.69 earnings per share. The firm’s revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, analysts forecast that Solventum will post 6.58 earnings per share for the current year.

Institutional Trading of Solventum

Several institutional investors and hedge funds have recently modified their holdings of SOLV. Independent Franchise Partners LLP increased its position in shares of Solventum by 19.0% during the fourth quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock valued at $1,216,785,000 after acquiring an additional 2,456,451 shares during the last quarter. Norges Bank bought a new position in Solventum in the 4th quarter valued at $147,467,000. Diamond Hill Capital Management Inc. grew its stake in Solventum by 152.2% in the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock valued at $167,119,000 after purchasing an additional 1,272,921 shares during the period. Boston Partners increased its position in shares of Solventum by 26.1% during the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after purchasing an additional 959,543 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Solventum by 20.0% during the 4th quarter. Geode Capital Management LLC now owns 4,588,728 shares of the company’s stock valued at $362,375,000 after purchasing an additional 763,308 shares during the last quarter.

Solventum News Roundup

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Quarterly earnings and revenue exceeded expectations. Solventum reported second-quarter adjusted EPS of $2.55, well above the $1.91 consensus and up from $1.69 a year earlier. Revenue reached $2.21 billion versus estimates of $2.15 billion, while organic sales increased 9.5%. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised its 2026 outlook. Solventum increased full-year adjusted EPS guidance to $7.10-$7.20, above the approximately $6.55 analyst consensus, and also raised its expectations for organic sales growth and free cash flow. Solventum Raises 2026 EPS Guidance
• Positive Sentiment: Analyst sentiment improved. Stifel Nicolaus raised its price target from $90 to $100 and upgraded Solventum to “buy,” implying approximately 18.9% potential upside from the cited price. This supports the view that the earnings beat and higher guidance could improve the company’s valuation. Benzinga Analyst Update
• Neutral Sentiment: Solventum plans to separate its Health Information Systems business. The company says the move will create a more focused MedTech company, allow the healthcare software business to pursue its own growth strategy and potentially unlock shareholder value. However, the separation will require execution and could create near-term uncertainty, particularly amid activist pressure to divest the business. Solventum to Separate Healthcare Software Business

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.